{"url_path":"/sec/dnli/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1714899/0001714899-26-000074-index.html","accession_number":"0001714899-26-000074","cik":"0001714899","ticker":"DNLI","issuer_name":"Denali Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1714899/0001714899-26-000074-index.html","primary_entity_key":"0001714899","primary_entity_name":"Denali Therapeutics Inc."},"word_count":250,"has_tables":true,"body_markdown":"Item 5.07     Submission of Matters to a Vote of Security Holders.\n\nOn June 3, 2026, Denali Therapeutics Inc. (the “Company”) held its annual meeting of stockholders. Of the 158,675,498 shares of common stock outstanding as of April 9, 2026, the record date for the meeting, 137,986,127 shares of common stock were represented at the meeting in person or by proxy, constituting 86.96% of the outstanding common stock entitled to vote. The matters voted upon at the meeting and the vote with respect to each such matter are set forth below:\n\nProposal 1 - Election of Directors\n\nElection of three Class III directors to hold office until the 2029 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.\n\nNomineesForWithheldBroker Non-Votes\n\nJennifer Cook75,998,25948,847,02913,140,839\n\nDavid Schenkein, M.D.91,814,68833,030,60013,140,839\n\nRyan Watts, Ph.D.121,220,5723,624,71613,140,839\n\nProposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm\n\nThe appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:\n\nForAgainstAbstainBroker Non-Votes\n\n137,516,267420,30549,555—\n\nProposal 3 - Advisory Vote to Approve Executive Compensation\n\nThe Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.\n\nForAgainstAbstainBroker Non-Votes\n\n117,038,7457,088,810717,73313,140,839"}